CurrentCignaPolicy IP0349

Susvimo

Cigna coverage policy for Susvimo (ranibizumab intravitreal injection via ocular implant) describing coverage stance, clinical rationale, safety concerns, coding and revision history for members under plans administered by Cigna Companies.

Policy Summary

PayerCigna

PolicySusvimo

Policy CodePolicy IP0349

Change TypeCoding & coverage revisions

Effective DateAug 15, 2025

Next Review Date

Key ActionWhen billing, providers must use the most appropriate codes as of the effective date; services not accompanied by covered codes under this Coverage Policy will be denied as not covered.

POLICY UPDATE CHANGES

Coding Information: Added coding table & HCPCS J2779.

Diabetic Macular Edema was added to the considered experimental/investigational/unproven section.

Diabetic Retinopathy was added to the Conditions Not Recommended for Approval section.

Annual revision noted: No criteria changes.

3Conditions Not Recommended for Approval

1HCPCS code listed as experimental

Coverage Determination

Ranibizumab intravitreal injection (Susvimo) is considered experimental, investigational, or unproven for the following indications due to insufficient data establishing safety, efficacy, and improved health outcomes:

Diabetic Macular Edema (DME): Approval is not recommended due to safety data including a Boxed Warning for endophthalmitis and other ocular adverse events; pivotal trial showed non-inferiority to monthly intravitreal ranibizumab injections but safety concerns remain (higher endophthalmitis rates reported in AMD trials and when including extensions, and other ocular adverse events more frequent with Susvimo).
Susvimo labeling includes a Boxed Warning regarding endophthalmitis; active-comparator AMD period showed 1.7% vs 0.5% endophthalmitis and 2% when including extensions; DME extension endophthalmitis 0.7%.
Diabetic Retinopathy: Approval is not recommended due to safety data; although efficacy signals were observed in the trial (e.g., ≥2-step ETDRS-DRSS improvement), Susvimo labeling includes a Boxed Warning for endophthalmitis and extension-phase endophthalmitis events were reported; other ocular adverse events were more frequent with Susvimo.
One endophthalmitis event reported in extension (0.8%); active-comparator AMD period 1.7% vs 0.5% and 2% including extensions.
Neovascular (Wet) Age-Related Macular Degeneration (AMD): Approval is not recommended due to safety data; although primary efficacy was equivalent to monthly intravitreal ranibizumab, Susvimo had higher rates of ocular adverse events and carries a Boxed Warning for endophthalmitis (3-fold higher in active-controlled AMD trials and 2% when including extensions).
Patients treated with Susvimo require regular monitoring for adverse events; many endophthalmitis cases were associated with conjunctival retraction/erosion.

Coverage stance: Not covered (considered experimental/investigational/unproven) for Susvimo (ranibizumab intravitreal injection via ocular implant). Scope: Cigna coverage policy for Susvimo describing the coverage stance, clinical rationale, safety concerns, coding, and revision history for members under plans administered by Cigna Companies. Effective date: 8/15/2025. Last review: 8/15/2025.

Provider Actions & Billing Impact

Documentation Required

Use appropriate billing codes

When billing, use the most appropriate codes as of the policy effective date. Services not accompanied by covered code(s) under this Coverage Policy will be denied as not covered.

J2779

Denial Risk

Claims for Susvimo in listed conditions at risk of denial

Claims for Susvimo (J2779) when billed for Diabetic Macular Edema, Diabetic Retinopathy, or Neovascular (wet) Age-Related Macular Degeneration are considered experimental/investigational/unproven and are subject to denial.

J2779 — Susvimo
Diabetic Macular Edema (DME)
Diabetic Retinopathy
Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Clinical Evidence & Safety Metrics

1.7%Endophthalmitis rate (AMD active comparator period): Susvimo vs monthly ranibizumab (1.7% vs 0.5%, ~3-fold higher)

2%All AMD trial phases (Susvimo): 2% (11/555) experienced endophthalmitis

0.7%DME extension (Susvimo): 0.7% (4/556) experienced endophthalmitis

0.8%Diabetic retinopathy extension (Susvimo): 0.8% (1/128) experienced endophthalmitis

Background evidence summary: Susvimo carries a unique Boxed Warning for endophthalmitis. Clinical trials showed higher rates of certain ocular adverse events with Susvimo compared with monthly intravitreal ranibizumab injections (for example, a 3-fold higher endophthalmitis rate in AMD trials: 1.7% vs. 0.5%, and 2% when including extension phases). Pivotal trials demonstrated non-inferior or equivalent efficacy to monthly ranibizumab injections, but the observed safety signals — particularly the boxed warning for endophthalmitis and increased ocular adverse events — are the primary reasons the policy does not recommend approval.

Background & Definitions

Susvimo is an intravitreal implant formulation of ranibizumab (ranibizumab intravitreal injection via ocular implant). Per FDA labeling, indications include diabetic macular edema (DME), diabetic retinopathy, and neovascular (wet) age-related macular degeneration (AMD) in patients who previously responded to at least two intravitreal VEGF injections. Susvimo has a Boxed Warning for endophthalmitis (unique among the VEGF inhibitors) and clinical trial safety signals include a higher rate of endophthalmitis in active-controlled AMD trials (1.7% vs. 0.5% for monthly ranibizumab) and 2% overall when extension phases are included. Other implant- or procedure-related warnings/precautions reported include rhegmatogenous retinal detachment, implant dislocation, vitreous hemorrhage, conjunctival erosion or retraction, conjunctival bleb, postoperative decrease in visual acuity, and implant-related technical issues. The HCPCS code J2779 identifies Susvimo as considered experimental/investigational/unproven in this policy.

Term	Definition
Susvimo	Ranibizumab intravitreal injection via ocular implant (Genentech)
Endophthalmitis	Severe intraocular infection/inflammation; listed as a boxed warning for Susvimo.

Revision History

5/15/2024annual_revision

Annual revision noted: No criteria changes.

2/15/2025coding_update

Added coding table and HCPCS code J2779 (Injection, ranibizumab, via intravitreal implant [Susvimo], 0.1 mg) to the Considered Experimental/Investigational/Unproven coding list.

6/15/2025policy_change

Material change: Diabetic Macular Edema (DME) was added to the considered experimental/investigational/unproven (not recommended) section due to safety concerns including boxed warning for endophthalmitis.

8/15/2025policy_changeLatest

Material change: Diabetic Retinopathy was added to the Conditions Not Recommended for Approval (not recommended) section due to safety concerns including boxed warning for endophthalmitis.